Abstract 1751P
Background
Myxoid liposarcoma (MLPS) constitutes around 15% of all liposarcoma. They are characterized by a specific translocation, the t(12;16), leading to the fusion of FUS to DDIT3, which confers specific molecular features. In this study, we assessed the clinical and survival data of MLPS pts (patients) with evaluation of the impact of various clinical and tumor features on survival outcomes.
Methods
This retrospective study included MLPS pts treated at Gustave Roussy between January 1990 and March 2024. All clinical features were gathered as well as survival data and management details. In addition, we performed univariate (UVA) and multivariate analyses (MVA) to evaluate the impact of various factors on survival (age, gender, adjuvant chemotherapy (CT) and radiation therapy (RT), primary site, and tumor grade (TG)).
Results
336 pts were included (median age of 43 yrs and 60.4% were men). They occurred in the lower arms (75.3%, 253 pts, most in the hip (73.1%)), followed by the trunk (9.8%, 33 pts). TG 1 tumor was in 172 pts (64.7%), TG 2 in 85 (31.9%), and TG 3 in 9 (3.4%). 311 pts had surgery (93.9%) of whom 165 had adjuvant RT (53.1%) while 78 received peri-operative CT (25.1%). Out of 317 pts, 85 had at least one local relapse (LR) (26.8%) with a median time to LR of 24.3 mo. At 6 mo, the LR-free survival (LR-FS) was 96% while the 1- and 5-year LRFS reached 92.2% and 75.8%. 95 had at least one metastatic relapse (MR) (30.3%) with a median time of 38.3 mo. [25.9;45.7]. At 6 mo., the MRFS was 98% while the 1- and 5-year reached 94.8% and 70.6%. The median OS was not reached (NR) [249; NR]. At 6 mo., the OS was 98.8% while the 1- and 5-year were 97.7% and 89.3%. In the UVA, adjuvant RT (p<0.001) and CT (p=0.008) had an impact on LR while in the MVA, adjuvant RT (p<0.001) and age (p=0.03) were significant. Male gender (p=0.01) and high TG (p=0.02) had a higher risk of MR as well as shorter survival (male gender (p=0.04) and TG (p=0.004)).
Conclusions
In one of the largest retrospective cohorts, 336 MLPS pts were commonly diagnosed with a tumor in the lower arms with a localized setting. It is characterized by a high risk of both local (26.8%) and distant relapse (30.3%) but with prolonged survival. Male gender and a higher tumor grade were associated with an increased risk of distant relapse and shorter survival.
Clinical trial identification
Editorial acknowledgement
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1393TiP - A phase II/III study to evaluate the optimal dose, safety, and efficacy of livmoniplimab (Livmo) in combination with budigalimab (Budi) plus chemotherapy (CT) vs pembrolizumab (Pembro) plus CT in untreated metastatic non-small cell lung cancer (mNSCLC)
Presenter: Nicolas Girard
Session: Poster session 06
1394TiP - KRYSTAL-7: A phase III study of first-line adagrasib plus pembrolizumab versus pembrolizumab alone in patients with advanced NSCLC with KRASG12C mutation
Presenter: Marina Garassino
Session: Poster session 06
1395TiP - A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)
Presenter: Antonio Passaro
Session: Poster session 06
1397TiP - Phase III trial of the therapeutic cancer vaccine OSE2101 versus docetaxel in patients with metastatic non-small cell lung cancer and secondary resistance to immunotherapy
Presenter: Stephen Liu
Session: Poster session 06
Resources:
Abstract
1398TiP - Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
Presenter: Solange Peters
Session: Poster session 06
1399TiP - Phase III, double-blind study of cannabis sativa extract in pain management and quality of life in patients with metastatic lung cancer: Protocol of a study (IPElife trial)
Presenter: Danielli Matias
Session: Poster session 06
1728P - Results of TNT: A phase II study using talimogene laherparepvec, nivolumab and trabectedin for advanced leiomyosarcoma and liposarcoma [NCT# 03886311]
Presenter: Sant Chawla
Session: Poster session 06
1729P - Update on SAINT: A phase II study using trabectedin (T) in combination with ipilimumab (I) and nivolumab (N) in previously treated soft tissue sarcoma
Presenter: Anmol Dia Agarwal
Session: Poster session 06